XPA

Summary

XPA (XPA, DNA damage recognition and repair factor, HGNC:12814) is a protein-coding gene on chromosome 9q22.33, encoding DNA repair protein complementing XP-A cells (P23025). Involved in DNA nucleotide excision repair (NER).

This gene encodes a zinc finger protein plays a central role in nucleotide excision repair (NER), a specialized type of DNA repair. NER is responsible for repair of UV radiation-induced photoproducts and DNA adducts induced by chemical carcinogens and chemotherapeutic drugs. The encoded protein interacts with DNA and several NER proteins, acting as a scaffold to assemble the NER incision complex at sites of DNA damage. Mutations in this gene cause Xeroderma pigmentosum complementation group A (XP-A), an autosomal recessive skin disorder featuring hypersensitivity to sunlight and increased risk for skin cancer.

Source: NCBI Gene 7507 — RefSeq curated summary.

At a glance

• Gene–disease (curated): xeroderma pigmentosum group A (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 4
• Clinical variants (ClinVar): 416 total — 58 pathogenic, 40 likely-pathogenic
• Phenotypes (HPO): 72
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_000380

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12814
Approved symbol	XPA
Name	XPA, DNA damage recognition and repair factor
Location	9q22.33
Locus type	gene with protein product
Status	Approved
Aliases	XPAC, XP1
Ensembl gene	ENSG00000136936
Ensembl biotype	protein_coding
OMIM	611153
Entrez	7507

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000375128, ENST00000462523, ENST00000485042, ENST00000496104, ENST00000905836, ENST00000905837

RefSeq mRNA: 2 — MANE Select: NM_000380 NM_000380, NM_001354975

CCDS: CCDS6729

Canonical transcript exons

ENST00000375128 — 6 exons

Exon	Start	End
ENSE00000805601	97689534	97689639
ENSE00000805603	97684923	97685040
ENSE00001465835	97697121	97697340
ENSE00003459576	97687096	97687261
ENSE00003465148	97693649	97693759
ENSE00003671978	97674909	97675587

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 93.58.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.8295 / max 244.0114, expressed in 1804 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101627	20.6894	1802
101628	1.1400	706

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	93.58	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.38	gold quality
left lobe of thyroid gland	UBERON:0001120	92.88	gold quality
tongue squamous epithelium	UBERON:0006919	92.70	gold quality
right lobe of thyroid gland	UBERON:0001119	92.66	gold quality
esophagus squamous epithelium	UBERON:0006920	92.59	gold quality
parietal pleura	UBERON:0002400	92.47	gold quality
thyroid gland	UBERON:0002046	92.43	gold quality
amniotic fluid	UBERON:0000173	92.19	gold quality
squamous epithelium	UBERON:0006914	92.16	gold quality
middle temporal gyrus	UBERON:0002771	91.87	gold quality
tendon	UBERON:0000043	91.81	gold quality
cervix squamous epithelium	UBERON:0006922	91.56	gold quality
epithelium of esophagus	UBERON:0001976	91.40	gold quality
lower esophagus mucosa	UBERON:0035834	91.38	gold quality
tibia	UBERON:0000979	91.31	gold quality
gingival epithelium	UBERON:0001949	91.24	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.17	gold quality
lower esophagus	UBERON:0013473	91.06	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.05	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.88	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.79	gold quality
cerebellar hemisphere	UBERON:0002245	90.78	gold quality
tibial artery	UBERON:0007610	90.69	gold quality
popliteal artery	UBERON:0002250	90.68	gold quality
sural nerve	UBERON:0015488	90.68	gold quality
cerebellar cortex	UBERON:0002129	90.66	gold quality
descending thoracic aorta	UBERON:0002345	90.62	gold quality
mucosa of stomach	UBERON:0001199	90.57	gold quality
palpebral conjunctiva	UBERON:0001812	90.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.44

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, DDB2, ERCC2, HIF1A, HMGA1, NR1H2, TCF3

miRNA regulators (miRDB)

13 targeting XPA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-4530	99.69	66.47	1509
HSA-MIR-12132	99.47	68.90	1341
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-3158-3P	98.45	64.25	560
HSA-MIR-6816-3P	95.05	66.08	459

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• modulates replication protein A-DNA interactions (PMID:11859086)
• Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions (PMID:11972036)
• Low amounts are sufficient to recover UV-resistance; demonstrate that XPA protein concentration is not a limiting factor for DNA repair (PMID:12082027)
• XPA A23G polymorphism contributes to genetic susceptibility for lung cancer (PMID:12376498)
• Dimerization of XPA plays an important role in the DNA damage recognition of nucleotide excision repair. (PMID:12390028)
• In patients, with xeroderma pigmentosum the severity of clinical symptoms depends on the length of the XPA gene products. (PMID:12459522)
• the multistep process of DNA damage recognition includes initiation by XPC-hHR23B, which is then replaced by the combined action of XPA and RPA (PMID:12486030)
• Xeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions (PMID:12897146)
• XPA, ERCC1 and XPF DNA repair protein expression is reduced in testis neoplasms (PMID:15095299)
• XPA was widely expressed in metastatic ovarian carcinoma effusion specimens and in the cells of the effusion microenvironment (PMID:15844177)
• The dominant form for XPA to efficiently bind to DNA damage is the XPA dimer; the concentration-dependent formation of different types of XPA-damaged DNA complex may play a role in cellular regulation of XPA activity. (PMID:15882075)
• Transfected XP12RO cell lines expressing 50,000 or more XPA molecules/cell showed UV resistance similar to normal cells. (PMID:16413230)
• These findings show how an increased deformability of damaged sites, leading to helical kinks recognized by XPA, contributes to target selectivity in DNA repair. (PMID:16491090)
• XPA polymorphism was associated with basal cell carcinoma and squamous cell carcinoma of the skin (PMID:16513681)
• Participants in a study of occupational exposure to mineral fibres in Slovakia were analysed for the polymorphism 23A–>G in the DNA repair gene XPA: presence of the A allele was associated with higher levels of DNA damage. (PMID:16613913)
• Data show that ultraviolet (UV) radiation-induced ATR signaling is compromised in XPA-deficient human cells during S phase, and this signaling involves UV bypass polymerase eta. (PMID:16675950)
• XPA recognizes undamaged DNA double-strand/single-strand (ds-ssDNA) junctions containing ssDNA branches with binding affinity much higher than its ability to bind to DNA damage. (PMID:17176115)
• results showed no interaction between the XPD Lys751Gln, XPA A23G, and XPD Asp312Asn polymorphisms and the environmental factors for the development of colorectal cancer (PMID:17363013)
• ING1b associates with chromatin in a UV-inducible manner and facilitates DNA access to nucleotide excision repair factor XPA. (PMID:17379210)
• Single nucleotide polymorphisms of xeroderma pigmentosum group A is associated with esophageal squamous cell carcinoma (PMID:17653764)
• The results indicate an increased basal cell carcinoma risk associated with high arsenic exposure among those homozygous variant for XPA (A23G). (PMID:17687452)
• removal of a single cationic side chain abolished DNA-binding activity and significant excision repair defects could be induced by single charge inversions on the XPA surface (PMID:17765667)
• RNA interference (RNAi) knockdown of XPA in Hutchinson-Gilford progeria syndrome cells partially restored double-strand breaks repair as evidenced by Western blot analysis, immunofluorescence and comet assays (PMID:17848622)
• Intake of fruit was associated with lower risk for lung cancer only among carriers of the XPA A23G variant genotype. (PMID:17913280)
• patients treated with first-line oxaliplatin/fluoropyrimidine harboring both XPG C/C and XPA A/G or A/A profiles have a longer survival and TTP. (PMID:18204222)
• although the amount of XPA in a testis tumor cell line is lower than normal, it is sufficient for nucleotide excision repair in vivo (PMID:18240296)
• Data suggest that lack of functional Xeroderma Pigmentosum A increases susceptibility of oxidative stress-induced genotoxicity while retaining cell viability posing as a potential cancer risk factor of Xeroderma Pigmentosum A patients. (PMID:18585952)
• XPA A23G and XPC exon 8 Val499Ala polymorphisms may be useful markers for identifying individuals at risk of developing gastric cardiac adenocarcinoma in the high incidence region of north China (PMID:18645534)
• Data show that XPC, XPA, and RPA demonstrate low specificity in binding to damaged DNA compared with undamaged DNA duplexes. (PMID:18774935)
• Differential association of alterations in FANCC and PTCH1 with that of PHF2, XPA and two breast cancer susceptibility genes (BRCA1/BRCA2) in the two age groups suggests differences in their molecular pathogenesis. (PMID:18990233)
• Genetic polymorphism in the XPA 23G might be associated with esophageal cancer. (PMID:19173862)
• Results show that Cep164 knockdown compromises the cell survival upon UV damage, and that UV irradiation significantly enhances the interaction between Cep164 and XPA. (PMID:19197159)
• Results showed that XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. (PMID:19430706)
• XPA formation of covalent adducts with DNA is due to the interaction of XPA with endogenous RPA. (PMID:19538122)
• the ATR-XPA interaction mediated by the helix-turn-helix motif of XPA plays an important role in DNA-damage responses to promote cell survival and genomic stability after UV irradiation. (PMID:19586908)
• the 5’-GTG-3’ sequence, containing 5R thymine glycol, paired with adenine, is a good binding substrate for XPA and XPC/HR23B. (PMID:19892827)
• Data show that mutation of two conserved residues (Asn-110 and Tyr-145) located in the XPA-binding site of ERCC1 dramatically affected NER. (PMID:19940136)
• genetic variations in XPA and XPC genes may modulate DNA damage levels when exposed to polycyclic aromatic hydrocarbons (PMID:20056640)
• The circadian oscillation of XPA is achieved both by regulation of transcription by the core circadian clock proteins including cryptochrome and by regulation at the posttranslational level by the HERC2 ubiquitin ligase. (PMID:20304803)
• Data show that XPC and Ku oppositely regulate the ubiquitin ligase activity of DDB2, and that DDB2 complex-mediated ubiquitylation plays a role in recruiting XPA to damaged sites. (PMID:20368362)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	xpa	ENSDARG00000038114
mus_musculus	Xpa	ENSMUSG00000028329
rattus_norvegicus	Xpa	ENSRNOG00000009576
drosophila_melanogaster	Xpac	FBGN0004832
caenorhabditis_elegans	xpa-1	WBGENE00006963

Protein

Protein identifiers

DNA repair protein complementing XP-A cells — P23025 (reviewed: P23025)

Alternative names: Xeroderma pigmentosum group A-complementing protein

All UniProt accessions (2): P23025, F2Z2T2

UniProt curated annotations — full annotation on UniProt →

Function. Involved in DNA nucleotide excision repair (NER). Initiates repair by binding to damaged sites with various affinities, depending on the photoproduct and the transcriptional state of the region. Required for UV-induced CHEK1 phosphorylation and the recruitment of CEP164 to cyclobutane pyrimidine dimmers (CPD), sites of DNA damage after UV irradiation. During NER stimulates the 5’-3’ helicase activity of XPD/ERCC2 and the DNA translocase activity of XPB/ERCC3. Connects XPD/ERCC2 and XPB/ERCC3 during NER, retaining DNA near the XPB/ERCC3 active site, and stabilizing the complex in a different conformation than in transcribing TFIIH.

Subunit / interactions. Interacts with GPN1. Interacts with RPA1 and RPA2; the interaction is direct and associates XPA with the RPA complex. Interacts (via N-terminus) with CEP164 upon UV irradiation. Interacts with HERC2. During NER binds XPD/ERCC2 and XPB/ERCC3 of transcription factor IIH (TFIIH), bridging the 2 proteins.

Subcellular location. Nucleus.

Tissue specificity. Expressed in various cell lines and in skin fibroblasts.

Post-translational modifications. ATR-dependent phosphorylation of XPA at Ser-196 is important for cell survival in response to UV damage. Ubiquitinated by HERC2 leading to degradation by the proteasome.

Disease relevance. Xeroderma pigmentosum complementation group A (XP-A) [MIM:278700] An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. The skin develops marked freckling and other pigmentation abnormalities. XP-A patients show the most severe skin symptoms and progressive neurological disorders. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the XPA family.

RefSeq proteins (2): NP_000371, NP_001341904 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000465	XPA/RAD14	Family
IPR009061	DNA-bd_dom_put_sf	Homologous_superfamily
IPR022652	Znf_XPA_CS	Conserved_site
IPR022656	XPA_C	Domain
IPR022658	XPA_CS	Conserved_site
IPR037129	XPA_sf	Homologous_superfamily

Pfam: PF01286, PF05181

UniProt features (46 total): sequence variant 11, strand 9, helix 6, turn 6, binding site 4, cross-link 3, modified residue 2, initiator methionine 1, chain 1, zinc finger region 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

18 structures.

PDB	Method	Resolution (Å)
6J44	X-RAY DIFFRACTION	2.06
6LAE	X-RAY DIFFRACTION	2.81
9QEC	ELECTRON MICROSCOPY	2.9
8EBU	ELECTRON MICROSCOPY	3.3
9PD3	ELECTRON MICROSCOPY	3.3
9PD4	ELECTRON MICROSCOPY	3.4
6RO4	ELECTRON MICROSCOPY	3.5
7AD8	ELECTRON MICROSCOPY	3.5
9XYU	ELECTRON MICROSCOPY	3.5
28KE	ELECTRON MICROSCOPY	3.6
8EBX	ELECTRON MICROSCOPY	3.6
8EBY	ELECTRON MICROSCOPY	3.6
8EBT	ELECTRON MICROSCOPY	3.9
9PCP	ELECTRON MICROSCOPY	4.3
9PD5	ELECTRON MICROSCOPY	5.7
1D4U	SOLUTION NMR
1XPA	SOLUTION NMR
2JNW	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23025-F1	82.51	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 105; 108; 126; 129

Post-translational modifications (5): 196, 63, 86, 145, 2

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5696395	Formation of Incision Complex in GG-NER
R-HSA-5696400	Dual Incision in GG-NER
R-HSA-6781823	Formation of TC-NER Pre-Incision Complex
R-HSA-6782135	Dual incision in TC-NER

MSigDB gene sets: 289 (showing top): REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER, GOBP_CHROMOSOME_ORGANIZATION, GOBP_REGULATION_OF_AUTOPHAGY, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_CELLULAR_RESPONSE_TO_UV, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_GROWTH, KAUFFMANN_DNA_REPAIR_GENES, MORF_PSMC2, GOBP_UV_PROTECTION, GOCC_NUCLEAR_REPLICATION_FORK, GOBP_NUCLEOTIDE_EXCISION_REPAIR, GOBP_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (16): nucleotide-excision repair, DNA damage recognition (GO:0000715), DNA repair (GO:0006281), base-excision repair (GO:0006284), nucleotide-excision repair (GO:0006289), response to oxidative stress (GO:0006979), intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630), response to toxic substance (GO:0009636), UV protection (GO:0009650), regulation of autophagy (GO:0010506), protein localization to nucleus (GO:0034504), multicellular organism growth (GO:0035264), positive regulation of transcription initiation by RNA polymerase II (GO:0060261), UV-damage excision repair (GO:0070914), nucleotide-excision repair involved in interstrand cross-link repair (GO:1901255), DNA damage response (GO:0006974), response to UV (GO:0009411)

GO Molecular Function (8): damaged DNA binding (GO:0003684), zinc ion binding (GO:0008270), protein domain specific binding (GO:0019904), protein homodimerization activity (GO:0042803), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (6): nucleotide-excision repair factor 1 complex (GO:0000110), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear body (GO:0016604), DNA replication factor A complex (GO:0005662)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Global Genome Nucleotide Excision Repair (GG-NER)	2
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA repair	3
nucleotide-excision repair	2
DNA damage response	2
cellular anatomical structure	2
chromosome organization	1
DNA metabolic process	1
response to stress	1
intrinsic apoptotic signaling pathway	1
response to chemical	1
response to UV	1
autophagy	1
regulation of catabolic process	1
protein localization to organelle	1
multicellular organismal process	1
developmental growth	1
transcription initiation at RNA polymerase II promoter	1
positive regulation of transcription by RNA polymerase II	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
cellular response to UV	1
interstrand cross-link repair	1
cellular response to stress	1
response to light stimulus	1
DNA binding	1
transition metal ion binding	1
protein binding	1
identical protein binding	1
protein dimerization activity	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
nucleotide-excision repair complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
nucleoplasm	1
intracellular membraneless organelle	1
nuclear replisome	1

Protein interactions and networks

STRING

1718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
XPA	ERCC1	P07992	999
XPA	ERCC3	P19447	998
XPA	ERCC2	P18074	998
XPA	RAD23B	P54727	995
XPA	ERCC4	Q92889	991
XPA	DDB2	Q92466	972
XPA	XAB2	Q9HCS7	972
XPA	ERCC5	P28715	959
XPA	RASSF1	Q9NS23	937
XPA	RPA2	P15927	936
XPA	A0A090J7P6	A0A090J7P6	921
XPA	XPC	Q01831	918
XPA	RECQL4	O94761	918
XPA	GPN1	Q9HCN4	916
XPA	ERCC6	Q03468	904

IntAct

115 interactions, top by confidence:

A	B	Type	Score
ERCC1	XPA	psi-mi:“MI:0915”(physical association)	0.930
XPA	ERCC1	psi-mi:“MI:0915”(physical association)	0.930
XPA	ERCC1	psi-mi:“MI:0914”(association)	0.930
XPA	ERCC1	psi-mi:“MI:0407”(direct interaction)	0.930
XPA	RPA2	psi-mi:“MI:0914”(association)	0.920
RPA2	XPA	psi-mi:“MI:0915”(physical association)	0.920
XPA	RPA2	psi-mi:“MI:0915”(physical association)	0.920
TRIM27	XPA	psi-mi:“MI:0915”(physical association)	0.720
XPA	NDEL1	psi-mi:“MI:0915”(physical association)	0.720
NDEL1	XPA	psi-mi:“MI:0915”(physical association)	0.720
XPA	HERC2	psi-mi:“MI:0914”(association)	0.680
XPA	HERC2	psi-mi:“MI:0915”(physical association)	0.680
SIRT1	XPA	psi-mi:“MI:0915”(physical association)	0.600
SIRT1	XPA	psi-mi:“MI:0197”(deacetylation reaction)	0.600

BioGRID (155): XPA (Two-hybrid), NDEL1 (Two-hybrid), ERCC4 (Affinity Capture-MS), ERCC1 (Affinity Capture-MS), NUP43 (Affinity Capture-MS), ZNF518A (Affinity Capture-MS), XPA (Affinity Capture-MS), XPA (Reconstituted Complex), RPA4 (Two-hybrid), ERCC1 (Affinity Capture-MS), ERCC4 (Affinity Capture-MS), NUP43 (Affinity Capture-MS), ZNF518A (Affinity Capture-MS), XPA (FRET), XPA (Affinity Capture-Western)

ESM2 similar proteins: A0A096LP55, A0A1D8PJT8, A1L243, A1L3N6, A6H767, A9ULB4, P00126, P00429, P05067, P07919, P08592, P12023, P13805, P14854, P23025, P27088, P28656, P36233, P36378, P48504, P55209, P56277, P79307, P99028, Q0P451, Q0VBY0, Q15545, Q28CA1, Q28EB4, Q2HJG8, Q4R374, Q4R5A5, Q4U0Y4, Q53CG4, Q5IS80, Q5M9I5, Q5R4D4, Q5R7L9, Q5RCT0, Q64267

Diamond homologs: O59753, P23025, P27088, P27089, P28518, P28519, P53709, Q64029, Q64267, Q5IRJ6, Q5PQZ3, Q5R4H0, Q6PML9

SIGNOR signaling

13 interactions.

A	Effect	B	Mechanism
ATR	up-regulates	XPA	phosphorylation
HERC2	down-regulates	XPA	ubiquitination
ATR	“up-regulates activity”	XPA	phosphorylation
XPA	“up-regulates activity”	DNA_repair
SIRT1	“up-regulates activity”	XPA	deacetylation
ATM	unknown	XPA	phosphorylation
RAD23B	“up-regulates activity”	XPA	binding
XPA	up-regulates	Nucleotide-excision_repair

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 51 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RNA Polymerase I Transcription Termination	5	40.8×	2e-05
Negative epigenetic regulation of rRNA expression	6	38.9×	2e-06
RNA Polymerase I Promoter Clearance	5	36.6×	2e-05
RNA Polymerase I Transcription	5	35.7×	2e-05
RNA Polymerase I Transcription Initiation	5	28.0×	7e-05
RNA Polymerase I Promoter Escape	5	15.2×	6e-04
NoRC negatively regulates rRNA expression	5	13.1×	1e-03
Epigenetic regulation of gene expression	6	10.7×	6e-04

GO biological processes:

GO term	Partners	Fold	FDR
mismatch repair	5	69.0×	5e-06
transforming growth factor beta receptor signaling pathway	5	16.9×	2e-03
spermatogenesis	9	6.7×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

416 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	58
Likely pathogenic	40
Uncertain significance	90
Likely benign	169
Benign	14

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1070563	NM_000380.4(XPA):c.113_117del (p.Leu38fs)	Pathogenic
1193397	NM_000380.4(XPA):c.253C>T (p.Gln85Ter)	Pathogenic
1357953	NM_000380.4(XPA):c.281del (p.Pro94fs)	Pathogenic
1379191	NM_000380.4(XPA):c.315C>A (p.Cys105Ter)	Pathogenic
1386503	NM_000380.4(XPA):c.20del (p.Ala7fs)	Pathogenic
1411593	NM_000380.4(XPA):c.436C>T (p.Gln146Ter)	Pathogenic
1457431	NM_000380.4(XPA):c.689dup (p.Arg231fs)	Pathogenic
1457433	NM_000380.4(XPA):c.540_541del (p.Tyr181fs)	Pathogenic
1459898	NC_000009.11:g.(?100451806)(100451931_?)del	Pathogenic
1709507	NM_000380.4(XPA):c.520C>T (p.Gln174Ter)	Pathogenic
1805601	NM_000380.4(XPA):c.640dup (p.Met214fs)	Pathogenic
190207	NM_000380.4(XPA):c.545_546insTA (p.Leu182fs)	Pathogenic
2008554	NM_000380.4(XPA):c.4_10dup (p.Ala4fs)	Pathogenic
2085090	NM_000380.4(XPA):c.70_80del (p.Val24fs)	Pathogenic
2167717	NM_000380.4(XPA):c.724dup (p.His242fs)	Pathogenic
264684	NM_000380.4(XPA):c.390-1G>C	Pathogenic
267185	NM_000380.4(XPA):c.553C>T (p.Gln185Ter)	Pathogenic
267186	NM_000380.4(XPA):c.374del (p.Thr125fs)	Pathogenic
2703119	NM_000380.4(XPA):c.238G>T (p.Glu80Ter)	Pathogenic
2735303	NM_000380.4(XPA):c.471_472del (p.Glu159fs)	Pathogenic
2735304	NM_000380.4(XPA):c.288del (p.Val97fs)	Pathogenic
2751195	NM_000380.4(XPA):c.140_149del (p.Pro47fs)	Pathogenic
2812711	NM_000380.4(XPA):c.754del (p.Asn251_Leu252insTer)	Pathogenic
2818886	NM_000380.4(XPA):c.124del (p.Arg42fs)	Pathogenic
2821876	NM_000380.4(XPA):c.509del (p.Pro170fs)	Pathogenic
2843471	NM_000380.4(XPA):c.408_409del (p.His136fs)	Pathogenic
2850447	NM_000380.4(XPA):c.712G>T (p.Glu238Ter)	Pathogenic
2863334	NM_000380.4(XPA):c.469A>T (p.Lys157Ter)	Pathogenic
2866510	NM_000380.4(XPA):c.424del (p.Thr142fs)	Pathogenic
2910231	NM_000380.4(XPA):c.103dup (p.Ala35fs)	Pathogenic

SpliceAI

1489 predictions. Top by Δscore:

Variant	Effect	Δscore
9:97675583:CAATT:C	acceptor_gain	1.0000
9:97675586:TT:T	acceptor_gain	1.0000
9:97675587:TCTGA:T	acceptor_loss	1.0000
9:97675588:C:CC	acceptor_gain	1.0000
9:97675588:C:T	acceptor_loss	1.0000
9:97675589:T:C	acceptor_loss	1.0000
9:97684919:CTAC:C	donor_loss	1.0000
9:97684920:TACC:T	donor_loss	1.0000
9:97684921:A:T	donor_loss	1.0000
9:97684922:C:CA	donor_loss	1.0000
9:97684928:A:AC	donor_gain	1.0000
9:97684929:C:CC	donor_gain	1.0000
9:97685037:CAAT:C	acceptor_gain	1.0000
9:97685039:AT:A	acceptor_gain	1.0000
9:97685039:ATCTA:A	acceptor_loss	1.0000
9:97685040:TCTAC:T	acceptor_loss	1.0000
9:97685041:C:CA	acceptor_loss	1.0000
9:97685041:C:CC	acceptor_gain	1.0000
9:97685042:T:A	acceptor_loss	1.0000
9:97687087:A:AC	donor_gain	1.0000
9:97687101:A:C	donor_gain	1.0000
9:97693642:A:AC	donor_gain	1.0000
9:97693643:C:CC	donor_gain	1.0000
9:97693643:CTTTA:C	donor_gain	1.0000
9:97693647:ACC:A	donor_loss	1.0000
9:97693648:CCTGG:C	donor_loss	1.0000
9:97693755:CATGC:C	acceptor_gain	1.0000
9:97693756:ATGC:A	acceptor_gain	1.0000
9:97693757:TGC:T	acceptor_gain	1.0000
9:97693758:GC:G	acceptor_gain	1.0000

AlphaMissense

1801 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:97687221:C:G	A144P	0.997
9:97693707:G:C	F75L	0.996
9:97693707:G:T	F75L	0.996
9:97693709:A:G	F75L	0.996
9:97687112:A:G	L180P	0.995
9:97689547:A:G	C126R	0.995
9:97689610:A:G	C105R	0.995
9:97675480:A:G	C261R	0.994
9:97675581:C:G	R227P	0.993
9:97687110:A:C	Y181D	0.993
9:97687202:A:G	L150P	0.992
9:97689546:C:T	C126Y	0.992
9:97687216:T:A	K145N	0.991
9:97687216:T:G	K145N	0.991
9:97687228:T:A	K141N	0.991
9:97687228:T:G	K141N	0.991
9:97689609:C:T	C105Y	0.991
9:97675470:C:G	C264S	0.990
9:97675471:A:G	C264R	0.990
9:97675471:A:T	C264S	0.990
9:97687117:C:A	M178I	0.990
9:97687117:C:G	M178I	0.990
9:97687117:C:T	M178I	0.990
9:97687146:T:C	N169D	0.990
9:97689545:A:C	C126W	0.990
9:97689546:C:G	C126S	0.990
9:97689547:A:T	C126S	0.990
9:97675478:A:C	C261W	0.989
9:97675479:C:G	C261S	0.989
9:97675480:A:T	C261S	0.989

dbSNP variants (sampled 300 via entrez): RS1000235312 (9:97683362 C>A,G), RS1000398500 (9:97693066 TA>T,TAA), RS1000486291 (9:97690020 G>A), RS1000511672 (9:97680219 GT>G,GTT), RS1000569297 (9:97657356 A>G), RS1000663303 (9:97688789 C>A,T), RS1000695069 (9:97696955 A>G), RS1000723416 (9:97664399 A>G), RS1000785700 (9:97682717 C>G), RS1000873744 (9:97692701 G>A,C), RS1000891972 (9:97664129 A>G), RS1000909949 (9:97695746 C>T), RS1001023464 (9:97657153 A>G), RS1001125053 (9:97656846 A>G), RS1001178391 (9:97697058 G>A,C,T)

Disease associations

OMIM: gene MIM:611153 | disease phenotypes: MIM:278700, MIM:167000

GenCC curated gene-disease

Disease	Classification	Inheritance
xeroderma pigmentosum group A	Definitive	Autosomal recessive
xeroderma pigmentosum	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
xeroderma pigmentosum group A	Definitive	AR

Mondo (3): xeroderma pigmentosum group A (MONDO:0010210), xeroderma pigmentosum (MONDO:0019600), ovarian cancer (MONDO:0008170)

Orphanet (3): Xeroderma pigmentosum (Orphanet:910), Rare ovarian cancer (Orphanet:213500), OBSOLETE: Xeroderma pigmentosum complementation group A (Orphanet:276249)

HPO phenotypes

72 total (30 of 72 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000135	Hypogonadism
HP:0000164	Abnormality of the dentition
HP:0000252	Microcephaly
HP:0000365	Hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000486	Strabismus
HP:0000491	Keratitis
HP:0000498	Blepharitis
HP:0000509	Conjunctivitis
HP:0000518	Cataract
HP:0000524	Conjunctival telangiectasia
HP:0000613	Photophobia
HP:0000621	Entropion
HP:0000648	Optic atrophy
HP:0000656	Ectropion
HP:0000958	Dry skin
HP:0000962	Hyperkeratosis
HP:0000963	Thin skin
HP:0000992	Cutaneous photosensitivity
HP:0000995	Melanocytic nevus
HP:0001009	Telangiectasia
HP:0001029	Poikiloderma
HP:0001034	Hypermelanotic macule
HP:0001053	Hypopigmented skin patches
HP:0001059	Pterygium
HP:0001072	Thickened skin
HP:0001249	Intellectual disability
HP:0001250	Seizure

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST000640_1	Thyroid cancer (Papillary, radiation-related)	5.000000e-12
GCST001762_338	Obesity-related traits	1.000000e-09
GCST002458_3	Serum thyroid-stimulating hormone levels	1.000000e-13
GCST003988_4	Hypothyroidism	1.000000e-89

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D014983	Xeroderma Pigmentosum	C04.834.867; C16.131.831.936; C16.320.850.970; C17.800.600.925; C17.800.621.936; C17.800.804.936; C17.800.827.970; C18.452.284.975

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105801 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1800975	Efficacy	3	Platinum compounds	Non-Small Cell Lung Carcinoma

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1800975	XPA	3	2.25	1	Platinum compounds

ChEMBL bioactivities

13 potent at pChembl≥5 of 24 total, top 13 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.09	IC50	820	nM	CHEMBL4065804
5.89	IC50	1300	nM	CHEMBL4085647
5.80	IC50	1600	nM	CHEMBL4068522
5.71	IC50	1930	nM	CHEMBL4087223
5.32	IC50	4820	nM	CHEMBL4080244
5.28	IC50	5230	nM	CHEMBL4098283
5.17	IC50	6800	nM	CHEMBL4095853
5.08	IC50	8400	nM	CHEMBL4089182
5.04	IC50	9100	nM	CHEMBL4088120
5.04	IC50	9100	nM	CHEMBL4096889
5.04	IC50	9100	nM	CHEMBL4080393
5.02	IC50	9600	nM	CHEMBL4059855
5.01	IC50	9800	nM	CHEMBL4083144

PubChem BioAssay actives

13 with measured affinity, of 68 total; 13 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-chloro-5-[(4Z)-4-[[5-(4-chloro-3-phenylmethoxycarbonylphenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	0.8200	uM
2-chloro-5-[(4Z)-4-[[5-[4-chloro-3-[(2-chlorophenyl)methoxycarbonyl]phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	1.3000	uM
2-chloro-5-[(4Z)-3-methyl-5-oxo-4-[[5-(3-propan-2-yloxycarbonylphenyl)furan-2-yl]methylidene]pyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	1.6000	uM
3-[(4Z)-4-[[5-[4-chloro-3-[(2-chlorophenyl)methoxycarbonyl]phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	1.9300	uM
3-[(4Z)-4-[[5-(4-chloro-3-ethoxycarbonylphenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	4.8200	uM
2-chloro-5-[(4Z)-4-[[5-(3-ethoxycarbonylphenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	5.2300	uM
2-chloro-5-[(4Z)-4-[[5-(4-chloro-3-prop-2-enoxycarbonylphenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	6.8000	uM
4-[(4Z)-4-[[5-[4-chloro-3-[(4-fluorophenyl)methylcarbamoyl]phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	8.4000	uM
3-[(4Z)-4-[[5-(3-butoxycarbonyl-4-chlorophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	9.1000	uM
4-[(4Z)-4-[[5-[4-chloro-3-(cyclopropylmethylcarbamoyl)phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	9.1000	uM
4-[(4Z)-4-[[5-[4-[(4-fluorophenyl)methylcarbamoyl]phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	9.1000	uM
5-[(4Z)-4-[[5-(3-butoxycarbonyl-4-chlorophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]-2-chlorobenzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	9.6000	uM
3-[(4Z)-4-[[5-[4-chloro-3-(cyclopropylmethylcarbamoyl)phenyl]furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1452151: Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA	ic50	9.8000	uM

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Zinc	affects binding, decreases reaction, increases activity, decreases activity	6
sodium arsenite	decreases reaction, decreases expression, increases abundance, affects expression, affects binding (+1 more)	5
Benzo(a)pyrene	affects localization, increases expression, decreases reaction, affects response to substance, affects cotreatment (+1 more)	5
Cisplatin	increases expression, decreases response to substance, decreases reaction, increases phosphorylation, increases reaction	4
2-chloroethyl ethyl sulfide	affects response to substance, decreases response to substance	2
Arsenic	decreases expression, increases abundance, decreases reaction, affects response to substance	2
Cadmium	affects binding	2
Mustard Gas	increases expression, decreases response to substance	2
Zidovudine	increases expression	2
Cadmium Chloride	decreases reaction, decreases activity, decreases expression	2
selenomethylselenocysteine	affects binding, decreases reaction	1
taxifolin	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
selenocystine	affects binding, decreases reaction	1
trichostatin A	decreases expression, decreases reaction, increases abundance	1
arsenite	affects reaction, decreases expression, increases expression	1
quinoline yellow	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	affects cotreatment, decreases expression, increases expression	1
fludarabine	decreases expression, affects cotreatment	1
ebselen	decreases reaction, affects binding	1
2-nitrophenyl selenocyanic acid	affects binding, decreases reaction	1
antimony trichloride	affects binding, decreases reaction	1
acylfulvene	increases response to substance	1
cisplatin-deoxy(guanosine monophosphate guanosine) adduct	decreases abundance	1
benzeneseleninic acid	affects binding, decreases reaction	1
Y 27632	increases expression	1
octylmethoxycinnamate	decreases expression	1
LAQ824	affects cotreatment, decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4020070	Binding	Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA at 12.5 to 100 uM by EMSA	Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. — J Med Chem

Cellosaurus cell lines

169 cell lines: 125 finite cell line, 21 transformed cell line, 11 induced pluripotent stem cell, 11 cancer cell line, 1 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1F08	XPHM1WI	Finite cell line	Female
CVCL_1F19	XPHF12BE	Finite cell line	Female
CVCL_1F20	XPHF12BE LCL	Transformed cell line	Female
CVCL_1F21	XPHM12BE	Finite cell line	Male
CVCL_1F22	XPHM12BE LCL	Transformed cell line	Male
CVCL_1F23	XPHM1WI LCL	Transformed cell line	Female
CVCL_3242	XP2OS(SV)	Transformed cell line	Female
CVCL_3245	XP3OS	Finite cell line	Female
CVCL_3246	XP3OS(SVT)	Transformed cell line	Female
CVCL_3247	XP35OS	Finite cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	PHASE4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	PHASE4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00001806	PHASE3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	PHASE3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	PHASE3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	PHASE3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002894	PHASE3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003214	PHASE3	COMPLETED	Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
NCT00003322	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003644	PHASE3	COMPLETED	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer